Ruben A. Mesa, MD, discusses mitigating racial disparities in myeloproliferative neoplasm clinical trials.
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses mitigating racial disparities in myeloproliferative neoplasm (MPN) clinical trials.
In myelofibrosis, a clinical trial that included patients from China provided key insight on how different patient populations respond to treatment, explains Mesa.
Moreover, this trial provided data on why some populations experience higher rates of anemia compared with others, Mesa says.
As the MPN space continues to expand, further diversifying accrual to clinical trials could potentially increase the chances of finding a cure for these diseases; however, teamwork is paramount, Mesa concludes.